[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336255-105":59,"doc-detail-336255-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","assay-validation-of-cell-free-dna-shallow-whole-genome-sequencing-to-determine-tumor-fraction-in-advanced-cancers","Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers","","Blood-based liquid biopsy is increasingly used in oncology, and tumor fraction (TFx)—the fraction of tumor-derived DNA among circulating cell-free DNA (cfDNA)—has shown clinical validity across cancer types. This article validates a low-cost approach using shallow whole-genome sequencing (WGS) of cfDNA from a single blood sample, paired with the computational pipeline ichorCNA. The study evaluates sensitivity, precision, repeatability, reproducibility, pre-analytic factors, and DNA quality/quantity, reporting TFx detection sensitivity from the 3% limit of detection and strong agreement across replicates and batches. It also compares EDTA vs Streck processing windows and recommends preferred cfDNA inputs for robust TFx quantitation for clinical application.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/assay-validation-of-cell-free-dna-shallow-whole-genome-sequencing-to-determine-tumor-fraction-in-advanced-cancers/336255/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/assay-validation-of-cell-free-dna-shallow-whole-genome-sequencing-to-determine-tumor-fraction-in-advanced-cancers/336255.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"What analytical metrics were evaluated during assay validation?","Question",{"text":112,"@type":113},"The validation assessed sensitivity (including the lower limit of detection), precision, repeatability across replicates, reproducibility across duplicate samples in different batches, and also examined pre-analytic factors and DNA quality/quantity requirements.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},336255,1790198590,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":131,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":132,"faqs":133,"seo_title":134,"seo_description":67,"update_tm":135,"read_time":136,"preview_page_count":19,"preview_urls":137},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Journal of Molecular Diagnostics, Vol. 26, No. 5, May 2024  \nAssay Validation of Cell-Free DNA Shallow   \nWhole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers  \nMicah Rickles-Young, * Gabriel Tinoco,yz Junko Tsuji, * Sam Pollock, * Marcy Haynam,zx Heather Lefebvre,zx Kristyn Glover,zx Dwight H. Owen,yz Katharine A. Collier,yz Gavin Ha,{ Viktor A. Adalsteinsson, * Carrie Cibulskis, * Niall J. Lennon, * and Daniel G. Stoveryzx  \nFrom the Genomics Platform,*Broad Institute of Harvard andMassachusetts Institute of Technology, Cambridge, Massachusetts; the Division ofMedical Oncology, y The Ohio State University College of Medicine, Columbus, Ohio;the Ohio State University Comprehensive Cancer Center,z Columbus, Ohio; the Stefanie Spielman Comprehensive Breast Center,x Columbus, Ohio; and the Public Health Sciences Division,{ Fred Hutchinson Cancer Research Center, Seattle, Washington  \nAccepted for publication January 18, 2024 .  \nAddress correspondence to Daniel G. Stover, M.D., Ohio State University Comprehensive Cancer Center, James Cancer Hospital, Columbus, OH 43210; or Niall J. Lennon, Ph.D., The Broad Institute of Harvard and MIT, 415 Main St., Cambridge, MA 02142 .  \nE-mail: daniel.stover@osumc. edu or nlennon@broadinstitute. org.  \nBlood-based liquid biopsy is increasingly used in clinical care of patients with cancer, and fraction of tumor-derived DNA in circulation (tumor fraction; TFx) has demonstrated clinical validity across multiple cancer types. To determine TFx, shallow whole-genome sequencing of cell-free DNA (cfDNA) can be performed from a single blood sample, using an established computational pipeline (ichorCNA), without prior knowledge of tumor mutations, in a highly cost-effective manner. We describe assay validation of this approach to facilitate broad clinical application, including evaluation of assay sensitivity, precision, repeatability, reproducibility, pre-analytic factors, and DNA quality/quantity. Sensitivity to detect TFx of 3%(lower limit of detection) was 97.2% to 100% at 1 􀀂 and 0.1 􀀂 mean sequencing depth, respectively. Precision was demonstrated on distinct sequencing instruments (HiSeqX and NovaSeq) with no observable differences. The assay achieved prespeciﬁed 95% agreement of TFx across replicates of the same specimen (repeatability) and duplicate samples in different batches (reproducibility) . Comparison of samples collected in EDTA and Streck tubes from single venipuncture in 23 patients demonstrated that EDTA or Streck tubes were comparable if processed within 8 hours. On the basis of a range of DNA inputs (1 to 50 ng), 20 ng cfDNA is the preferred input, with 5 ng minimum acceptable. Overall, this shallow whole-genome sequencing of cfDNA and ichorCNA approach offers sensitive, precise, and reproducible quantitation of TFx, facilitating assay application in clinical cancer care.(J Mol Diagn 2024, 26: 413e422; [https://doi.org/10.1016/j.jmoldx.2024.01.014](https://doi.org/10.1016/j.jmoldx.2024.01.014))  \nNext-generation sequencing technologies are capable of detecting small amounts of cell-free DNA (cfDNA) shed by normal and malignant cells into the circulation, making the blood an accessible repository for real-time genomic proﬁles of tumors. There are growing data that the fraction of tumorderived DNA among total cfDNA (tumor fraction; TFx) is prognostic and may be useful in cancer detection, and changes in TFx may serve as an early identiﬁer for patients responding, or failing to respond, to therapy. 1e9  \nEarly efforts to calculate cfDNA TFx focused on a personalized assay approach, in which mutations are identiﬁed through tumor sequencing, then mutation-speciﬁc primers synthesized to probe cfDNA from plasma.2, 10e12  \nThis approach requires both tumor biopsy and germline sequencing, complex analyses, and time-consuming probe generation. Personalized assays and panel sequencing approaches are expensive (Figure 1A) . Analysis of wholeexome sequencing (WES) of cf","cbCaii2tZETRvRuU","https://ap.wps.com/l/cbCaii2tZETRvRuU","pdf",2391880,"English","# Assay validation overview\n## Clinical rationale for tumor fraction from cfDNA\n## Computational approach using ichorCNA\n## Analytical performance: sensitivity and precision\n## Repeatability and reproducibility\n## Pre-analytic factors and processing tubes\n## DNA input requirements and recommended inputs","[{\"question\":\"What analytical metrics were evaluated during assay validation?\",\"answer\":\"The validation assessed sensitivity (including the lower limit of detection), precision, repeatability across replicates, reproducibility across duplicate samples in different batches, and also examined pre-analytic factors and DNA quality/quantity requirements.\"}]","Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers | PDF",1790014276,25,[138,142,146,150],{"page_no":8,"url":139,"width":140,"height":141},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4af9db4adc77006b6721771047f867d.webp",983,1315,{"page_no":14,"url":143,"width":144,"height":145},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be875516ff7cfedb55c8f767ff52da58.webp",982,1314,{"page_no":81,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b61302f573df860d8f931182c2b3247.webp",981,1312,{"page_no":19,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4db13fcccc42e95f398e494ee10d874.webp",980,1311]